Published in Neurosci Lett on March 15, 2010
Long non-coding RNAs: novel targets for nervous system disease diagnosis and therapy. Neurotherapeutics (2013) 1.02
Endoplasmic reticulum stress in skeletal muscle homeostasis and disease. Curr Rheumatol Rep (2012) 0.94
ER-stress in Alzheimer's disease: turning the scale? Am J Neurodegener Dis (2013) 0.91
Activation of the ubiquitin proteasome pathway in a mouse model of inflammatory myopathy: a potential therapeutic target. Arthritis Rheum (2013) 0.81
BACE-1, PS-1 and sAPPβ levels are increased in plasma from sporadic inclusion body myositis patients: surrogate biomarkers among inflammatory myopathies. Mol Med (2015) 0.75
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
Expression of a noncoding RNA is elevated in Alzheimer's disease and drives rapid feed-forward regulation of beta-secretase. Nat Med (2008) 5.62
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Regulatory roles of natural antisense transcripts. Nat Rev Mol Cell Biol (2009) 4.48
The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods (2005) 3.40
Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms. EMBO Rep (2006) 2.96
Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry (2003) 2.85
Non-coding RNAs: new players in eukaryotic biology. Gene (2005) 2.29
Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J Biol Chem (2006) 2.09
Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol (2006) 1.80
Transcriptional and translational regulation of BACE1 expression--implications for Alzheimer's disease. Prog Neurobiol (2006) 1.75
What do natural antisense transcripts regulate? RNA Biol (2009) 1.66
Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today (2006) 1.61
p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol (2009) 1.51
Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol (2004) 1.44
Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J (2006) 1.36
Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol (2008) 1.29
Noncoding RNAs: couplers of analog and digital information in nervous system function? Trends Neurosci (2007) 1.27
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol (2009) 1.25
Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology (2006) 1.18
Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique. Neurology (1993) 1.11
Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem (2006) 1.06
Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol (2009) 1.01
Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease. Cell Mol Life Sci (2008) 0.96
Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol (2006) 0.93
Increase of nitric oxide synthases and nitrotyrosine in inclusion-body myositis. Neuroreport (1996) 0.93
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol (2007) 0.91
BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol (2003) 0.91
Natural antisense transcripts are co-expressed with sense mRNAs in synaptoneurosomes of adult mouse forebrain. Neurosci Res (2008) 0.89
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol (2005) 0.88
Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis muscle fibers. Neurobiol Aging (2008) 0.87
In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med (2008) 0.86
Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet (2001) 0.84
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology (2006) 1.87
p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol (2009) 1.51
Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle. Am J Pathol (2004) 1.44
Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains. Acta Neuropathol (2008) 1.29
Guidelines for the diagnosis and treatment of chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst (2003) 1.26
Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol (2009) 1.25
Inclusion-body myositis: clinical, diagnostic, and pathologic aspects. Neurology (2006) 1.18
Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol (2005) 1.12
Pathogenic considerations in sporadic inclusion-body myositis, a degenerative muscle disease associated with aging and abnormalities of myoproteostasis. J Neuropathol Exp Neurol (2012) 1.07
Homocysteine-induced endoplasmic reticulum protein (Herp) is up-regulated in sporadic inclusion-body myositis and in endoplasmic reticulum stress-induced cultured human muscle fibers. J Neurochem (2006) 1.06
Impaired autophagy in sporadic inclusion-body myositis and in endoplasmic reticulum stress-provoked cultured human muscle fibers. Am J Pathol (2010) 1.05
Amyloid-beta42 is preferentially accumulated in muscle fibers of patients with sporadic inclusion-body myositis. Acta Neuropathol (2009) 1.01
Inclusion-body myositis and myopathies: different etiologies, possibly similar pathogenic mechanisms. Curr Opin Neurol (2002) 0.97
Endoplasmic reticulum stress induces myostatin precursor protein and NF-kappaB in cultured human muscle fibers: relevance to inclusion body myositis. Exp Neurol (2006) 0.93
Abnormalities of NBR1, a novel autophagy-associated protein, in muscle fibers of sporadic inclusion-body myositis. Acta Neuropathol (2011) 0.92
Inclusion-body myositis, a multifactorial muscle disease associated with aging: current concepts of pathogenesis. Curr Opin Rheumatol (2007) 0.92
BACE1 and BACE2 in pathologic and normal human muscle. Exp Neurol (2003) 0.91
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. Acta Neuropathol (2007) 0.91
Molecular pathology and pathogenesis of inclusion-body myositis. Microsc Res Tech (2005) 0.90
Cystatin C colocalizes with amyloid-beta and coimmunoprecipitates with amyloid-beta precursor protein in sporadic inclusion-body myositis muscles. J Neurochem (2003) 0.90
AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord (2006) 0.88
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. Acta Neuropathol (2005) 0.88
Decreased SIRT1 deacetylase activity in sporadic inclusion-body myositis muscle fibers. Neurobiol Aging (2008) 0.87
Novel demonstration of conformationally modified tau in sporadic inclusion-body myositis muscle fibers. Neurosci Lett (2011) 0.87
In inclusion-body myositis muscle fibers Parkinson-associated DJ-1 is increased and oxidized. Free Radic Biol Med (2008) 0.86
Newest pathogenetic considerations in inclusion-body myositis: possible role of amyloid-beta, cholesterol, relation to aging and to Alzheimer's disease. Curr Rheumatol Rep (2002) 0.86
Unicorns, dragons, polymyositis, and other mythical beasts. Neurology (2004) 0.83
Proposed pathogenetic cascade of inclusion-body myositis: importance of amyloid-beta, misfolded proteins, predisposing genes, and aging. Curr Opin Rheumatol (2003) 0.83
Luminescent conjugated oligothiophenes for sensitive fluorescent assignment of protein inclusion bodies. Chembiochem (2013) 0.82
Sporadic inclusion-body myositis: A degenerative muscle disease associated with aging, impaired muscle protein homeostasis and abnormal mitophagy. Biochim Biophys Acta (2014) 0.82
Transthyretin Val122Ile, accumulated Abeta, and inclusion-body myositis aspects in cultured muscle. Neurology (2003) 0.82
Expression of Nogo-A in human muscle fibers is not specific for amyotrophic lateral sclerosis. Ann Neurol (2007) 0.81
Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol (2010) 0.81
Dysferlin is a newly identified binding partner of AβPP and it co-aggregates with amyloid-β42 within sporadic inclusion-body myositis (s-IBM) muscle fibers. Acta Neuropathol (2013) 0.81
Unfolding story of inclusion-body myositis and myopathies: role of misfolded proteins, amyloid-beta, cholesterol, and aging. J Child Neurol (2003) 0.80
Sporadic inclusion-body myositis: a proposed key pathogenetic role of the abnormalities of the ubiquitin-proteasome system, and protein misfolding and aggregation. Acta Myol (2005) 0.77
Activation of the γ-secretase complex and presence of γ-secretase-activating protein may contribute to Aβ42 production in sporadic inclusion-body myositis muscle fibers. Neurobiol Dis (2012) 0.77
Activation of the Unfolded Protein Response in Sporadic Inclusion-Body Myositis but Not in Hereditary GNE Inclusion-Body Myopathy. J Neuropathol Exp Neurol (2015) 0.76
Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2009) 0.75
Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2010) 0.75
Sodium phenylbutyrate reverses lysosomal dysfunction and decreases amyloid-β42 in an in vitro-model of inclusion-body myositis. Neurobiol Dis (2014) 0.75